BACKGROUND: The classification of acute myeloid leukemia (AML) FAB subtype M7 relies on immunophenotypic assessment. CD41 is expressed throughout all stages of maturation of megakaryocytes and has therefore been described as a specific blast cell marker in AML M7 as well as in transient myeloproliferative disease (TMD) of patients with Down syndrome (DS). However, technical difficulties underlie the need for new markers for these entities. METHODS: We evaluated the expression of human lymphocyte function-associated antigen 1 (CD11a) in a large cohort of pediatric AML and TMD patients (n = 91) of the Austrian AML-BFM 98 and 2004 studies. RESULTS: We found a consistent deficiency of CD11a as assessed by mean fluorescence intensity in all patients with non-DS AML M7 (n = 8) and M6 (n = 1), all cases of classical DS-AML (n = 12) as well as TMD (n = 15) that was statistically significant in comparison to non-DS AML M0-M5 patients (n = 55; P < 0.001, sensitivity 100%). Only three of 55 Non-DS M0-5 patients were CD11a deficient (specificity 95%). Monocytic leukemias (M4/5) and normal monocytes typically showed a high CD11a expression, FAB types M1/2 and normal neutrophils an intermediate expression level, while all M3 leukemias were rather low in CD11a expression. CONCLUSIONS: We conclude, that deficiency of CD11a expression should be added to the diagnostic criteria of AML-M7, classical DS-AML and TMD.
BACKGROUND: The classification of acute myeloid leukemia (AML) FAB subtype M7 relies on immunophenotypic assessment. CD41 is expressed throughout all stages of maturation of megakaryocytes and has therefore been described as a specific blast cell marker in AML M7 as well as in transient myeloproliferative disease (TMD) of patients with Down syndrome (DS). However, technical difficulties underlie the need for new markers for these entities. METHODS: We evaluated the expression of humanlymphocyte function-associated antigen 1 (CD11a) in a large cohort of pediatric AML and TMDpatients (n = 91) of the Austrian AML-BFM 98 and 2004 studies. RESULTS: We found a consistent deficiency of CD11a as assessed by mean fluorescence intensity in all patients with non-DS AML M7 (n = 8) and M6 (n = 1), all cases of classical DS-AML (n = 12) as well as TMD (n = 15) that was statistically significant in comparison to non-DS AML M0-M5 patients (n = 55; P < 0.001, sensitivity 100%). Only three of 55 Non-DS M0-5 patients were CD11a deficient (specificity 95%). Monocytic leukemias (M4/5) and normal monocytes typically showed a high CD11a expression, FAB types M1/2 and normal neutrophils an intermediate expression level, while all M3 leukemias were rather low in CD11a expression. CONCLUSIONS: We conclude, that deficiency of CD11a expression should be added to the diagnostic criteria of AML-M7, classical DS-AML and TMD.
Authors: Eline J M Bertrums; C Michel Zwaan; Daisuke Hasegawa; Valerie De Haas; Dirk N Reinhardt; Franco Locatelli; Barbara De Moerloose; Michael Dworzak; Arjan Buijs; Petr Smisek; Alexandra Kolenova; Cornelis Jan Pronk; Jan-Henning Klusmann; Ana Carboné; Alina Ferster; Evangelia Antoniou; Soheil Meshinchi; Susana C Raimondi; Charlotte M Niemeyer; Henrik Hasle; Marry M Van den Heuvel-Eibrink; Bianca F Goemans Journal: Haematologica Date: 2022-03-01 Impact factor: 9.941
Authors: Nienke Brouwer; Sergio Matarraz; Stefan Nierkens; Mattias Hofmans; Michaela Nováková; Elaine Sobral da Costa; Paula Fernandez; Anne E Bras; Fabiana Vieira de Mello; Ester Mejstrikova; Jan Philippé; Georgiana Emilia Grigore; Carlos E Pedreira; Jacques J M van Dongen; Alberto Orfao; Vincent H J van der Velden Journal: Cancers (Basel) Date: 2022-03-21 Impact factor: 6.639